Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 27.02.18 in Vol 4, No 1 (2018): Jan-Mar

This paper is in the following e-collection/theme issue:

Works citing "Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study"

Corinne M Hohl, Serena S Small, David Peddie, Katherin Badke, Chantelle Bailey, Ellen Balka

JMIR Public Health Surveill 2018 (Feb 27); 4(1):e21 

According to Crossref, the following articles are citing this article (DOI 10.2196/publichealth.9282):

(note that this is only a small subset of citations)

  1. Peddie D, Small SS, Badke K, Bailey C, Balka E, Hohl CM. Adverse Drug Event Reporting From Clinical Care: Mixed-Methods Analysis for a Minimum Required Dataset. JMIR Medical Informatics 2018;6(2):e10248
    CrossRef
  2. Small SS, Hohl CM, Balka E. Organizational implications of implementing a new adverse drug event reporting system for care providers and integrating it with provincial health information systems. Healthcare Management Forum 2019;32(4):208
    CrossRef
  3. Adenuga BA, Kibuule D, Bamitale KDS, Rennie TW. Effective integration of pharmacovigilance systems at public health facilities in resource-limited settings: A qualitative study. Research in Social and Administrative Pharmacy 2020;16(8):1111
    CrossRef
  4. Abramova N, Hubbard J, Schertz J, Richter E. Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development. Drug Safety 2019;42(3):453
    CrossRef
  5. Güner MD, Ekmekci PE. Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. Journal of Drug Assessment 2019;8(1):13
    CrossRef
  6. Graham M, Lucas CJ, Schneider J, Martin JH, Hall W. Translational hurdles with cannabis medicines. Pharmacoepidemiology and Drug Safety 2020;29(10):1325
    CrossRef
  7. Esquivel A, Mendoza G, Soria R, Velázquez N. Pharmacovigilance of Antivenoms in Toxicological Emergencies. Latin american journal of clinical sciences and medical technology 2019;1(1):8
    CrossRef
  8. Hau JP, Brasher PMA, Cragg A, Small S, Wickham M, Hohl CM. Using ActionADE to create information continuity to reduce re-exposures to harmful medications: study protocol for a randomized controlled trial. Trials 2021;22(1)
    CrossRef
  9. Gras M, Gras-Champel V, Moragny J, Delaunay P, Laugier D, Masmoudi K, Liabeuf S. Impact of the COVID-19 outbreak on the reporting of adverse drug reactions associated with self-medication. Annales Pharmaceutiques Françaises 2021;79(5):522
    CrossRef
  10. Kurteva S, Abrahamowicz M, Gomes T, Tamblyn R. Association of Opioid Consumption Profiles After Hospitalization With Risk of Adverse Health Care Events. JAMA Network Open 2021;4(5):e218782
    CrossRef
  11. . Pharmacovigilance: Present Scenario and Future Goals. International Journal of Research Foundation of Hospital and Healthcare Administration 2018;6(2):91
    CrossRef
  12. Zorzela L, Khamba B, Sparks E, Necyk C, Urichuk L, Katzman MA, Koczerginski D, Chue P, Barnes J, Vohra S. Study of Natural Products Adverse Reactions (SONAR) in Adults with Mental Health Conditions: A Cross-Sectional Study. Drug Safety 2021;44(9):999
    CrossRef
  13. Pittau B, Palla P, Pettinau F, Mastino A. A New Tool for an Awareness Plan Concerning Critical Issues, Needs and Attitudes of Citizens on the Use of Medicines. Healthcare 2021;9(11):1409
    CrossRef
  14. Li R, Curtis K, Van C, Tabish Razi Zaidi S, Yeo CY, Arun Kali C, Zaheen M, Therese Moujalli G, Castelino R. Why hospital-based healthcare professionals do not report adverse drug reactions: a mixed methods study using the Theoretical Domains Framework. European Journal of Clinical Pharmacology 2022;78(7):1165
    CrossRef
  15. Fossouo Tagne J, Yakob RA, Mcdonald R, Wickramasinghe N. Barriers and Facilitators Influencing Real-time and Digital-Based Reporting of Adverse Drug Reactions by Community Pharmacists: Qualitative Study Using the Task-Technology Fit Framework. Interactive Journal of Medical Research 2022;11(2):e40597
    CrossRef
  16. George DM, Palatty PL. Pattern of adverse drug reactions to anticancer drugs at an apex hospital in south India: A retrospective study. Indian Journal of Pharmacy and Pharmacology 2022;9(3):191
    CrossRef
  17. Fossouo Tagne J, Yakob RA, Mcdonald R, Wickramasinghe N. Linking Activity Theory Within User-Centered Design: Novel Framework to Inform Design and Evaluation of Adverse Drug Reaction Reporting Systems in Pharmacy. JMIR Human Factors 2023;10:e43529
    CrossRef
  18. Lim R, Thornton C, Stanek J, Ellett LK, Thiessen M. Development of a Web-Based System to Report Medication-Related Adverse Effects: Design and Usability Study. JMIR Formative Research 2022;6(10):e37605
    CrossRef
  19. Chan E, Small SS, Wickham ME, Cheng V, Balka E, Hohl CM. The Utility of Different Data Standards to Document Adverse Drug Event Symptoms and Diagnoses: Mixed Methods Study. Journal of Medical Internet Research 2021;23(12):e27188
    CrossRef
  20. Skutezky T, Small SS, Peddie D, Balka E, Hohl CM. Beliefs and perceptions of patient safety event reporting in a Canadian Emergency Department: a qualitative study. Canadian Journal of Emergency Medicine 2022;24(8):867
    CrossRef
  21. Fossouo Tagne J, Yakob RA, Dang TH, Mcdonald R, Wickramasinghe N. Reporting, Monitoring, and Handling of Adverse Drug Reactions in Australia: Scoping Review. JMIR Public Health and Surveillance 2023;9:e40080
    CrossRef
  22. Lambert BL, Schiff GD. RaDonda Vaught, medication safety, and the profession of pharmacy: Steps to improve safety and ensure justice. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY 2022;5(9):981
    CrossRef
  23. Tiemersma EW, Ali I, Alemu A, Avong YK, Duga A, Elagbaje C, Isah A, Kay A, Mmbaga BT, Mmari E, Mwamwitwa K, Nhlabatsi S, Sintayehu K, Arefayne A, Teferi M, Cobelens F, Härmark L. Baseline assessment of pharmacovigilance activities in four sub-Saharan African countries: a perspective on tuberculosis. BMC Health Services Research 2021;21(1)
    CrossRef
  24. Ali S, Curtain CM, Bereznicki LR, Salahudeen MS. Actual drug-related harms in residential aged care facilities: a narrative review. Expert Opinion on Drug Safety 2022;21(8):1047
    CrossRef
  25. Stone KD, Scott K, Holroyd BR, Lang E, Yee K, Taghizadeh N, Deol J, Dong K, Fanaeian J, Ghosh M, Low K, Ross M, Tanguay R, Faris P, Day N, McLane P. Buprenorphine/naloxone initiation and referral as a quality improvement intervention for patients who live with opioid use disorder: quantitative evaluation of provincial spread to 107 rural and urban Alberta emergency departments. Canadian Journal of Emergency Medicine 2023;25(7):598
    CrossRef
  26. Zitu MM, Zhang S, Owen DH, Chiang C, Li L. Generalizability of machine learning methods in detecting adverse drug events from clinical narratives in electronic medical records. Frontiers in Pharmacology 2023;14
    CrossRef
  27. Alloush R, van Lint J, van Marum RJ, Hermens WW, Jessurun NT. Hospital registration of adverse drug reactions in electronic health records: importance and contribution to pharmacovigilance. Expert Opinion on Drug Safety 2023;:1
    CrossRef
  28. Kurteva S, Abrahamowicz M, Beauchamp M, Tamblyn R. Comparison of Different Modeling Approaches for Prescription Opioid Use and Its Association With Adverse Events. American Journal of Epidemiology 2023;192(9):1592
    CrossRef
  29. Fossouo Tagne J, Yakob RA, Mcdonald R, Wickramasinghe N. A Web-Based Tool to Report Adverse Drug Reactions by Community Pharmacists in Australia: Usability Testing Study. JMIR Formative Research 2023;7:e48976
    CrossRef
  30. Cragg A, Small SS, Lau E, Rowe A, Lau A, Butcher K, Hohl CM. Sharing Adverse Drug Event Reports Between Hospitals and Community Pharmacists to Inform Re-dispensing: An Analysis of Reports and Process Outcomes. Drug Safety 2023;46(11):1161
    CrossRef
  31. Christ P, Dubrall D, Schmid M, Sachs B. Comparative Analysis of Information Provided in German Adverse Drug Reaction Reports Sent by Physicians, Pharmacists and Consumers. Drug Safety 2023;46(12):1363
    CrossRef
  32. Lau EY, Cragg A, Small SS, Butcher K, Hohl CM. Characterizing and Comparing Adverse Drug Events Documented in 2 Spontaneous Reporting Systems in the Lower Mainland of British Columbia, Canada: Retrospective Observational Study. JMIR Human Factors 2024;11:e52495
    CrossRef
  33. Rapaić A, Milošević E, Todorović N, Janjić N, Lalić-Popović M, Milošević N. Suspected Hematuria: Adverse Effects of Rivaroxaban in Older Adult Treated for Atrial Fibrillation. Reports 2024;7(1):11
    CrossRef
  34. Wickham ME, McGrail KM, Law MR, Cragg A, Hohl CM. Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events. British Journal of Clinical Pharmacology 2024;
    CrossRef